A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy

Abstract

The purpose of this study is to is to evaluate the occurrence of late onset (i.e., greater than 5 years after treatment) adverse events of special interest (AESI) in participants who have received sub-retinal transplant of human embryonic stem cell derived - retinal pigment epithelial (hESC-RPE) cells in an AIRM-sponsored clinical trial. The events of special interest are adverse events (AEs) that are presumed to have a potential causal relationship to the hESC-RPE cells. Phase: PHASE1, PHASE2 Status: ENROLLING_BY_INVITATION Conditions: Macular Degenerative Disease Interventions: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells

Keywords

Sources